I'd be surprised if there haven't been offers to license MPL. The initial fee would fund the study but the milestone payments are only realised after approval. Therefore licensing offers a low risk opportunity for BP to participate in a potential blockbuster. If MPL gains FDA approval the greater returns to shareholders will always be gained by avoiding licensing deals and selling the whole thing. I would prefer to wait and see this thing through. It will be worth billions if successful.
I'd be surprised if there haven't been offers to...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.08M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 179589 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.00pm 19/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable